Paper Details

  1. Home
  2. Paper Details

Rituximab for rheumatoid arthrits treatment: a systematic review.

Author: AcurcioFrancisco de Assis, AlmeidaAlessandra Maciel, BarbosaMariana Michel, CostaJuliana de Oliveira, Guerra JúniorAugusto Afonso, KakehasiAdriana Maria, MachadoMarina Amaral de Ávila, de AraújoVânia Eloísa, de LemosLívia Lovato Pires

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Rheumatoid arthritis (RA) is a chronic condition that causes inflammation in the joints, leading to disability. While several medications have proven effective, some patients don't respond well. Rituximab, a type of antibody medication, is used for these patients.
Paper Details　
Original Abstract of the Article :
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by systemic joint inflammation that often leads to significant disability. Several effective anti-TNF agents have been used, but some patients have shown an inadequate response. Rituximab is a therapeutic monoclonal antibody ind...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/25054600

データ提供：米国国立医学図書館（NLM）

Rituximab: A New Hope for Rheumatoid Arthritis?

[Rheumatoid arthritis (RA)] is a chronic autoimmune disease that can significantly impact quality of life. While several treatments have been developed, some patients may not respond adequately to conventional therapies. This study investigates the effectiveness of [rituximab], a monoclonal antibody, in managing RA in patients who have not responded to other therapies. The researchers conducted a [systematic review] to synthesize the existing evidence and assess the overall impact of rituximab on RA treatment.

Rituximab: A Potential Option for Refractory Rheumatoid Arthritis

The review revealed that rituximab can be an effective treatment option for patients with RA who have not responded adequately to other therapies, including [anti-TNF agents]. While further research is needed to optimize its use and understand its long-term implications, rituximab shows promise as a potential treatment for patients with refractory RA.

Navigating the Treatment Landscape: Understanding the Options

This study provides valuable information for healthcare professionals navigating the complex landscape of RA treatment. The findings highlight the need for personalized treatment approaches, recognizing that different patients may respond differently to various therapies. Rituximab emerges as a potential option for patients who have not found relief from conventional therapies, offering hope for a better quality of life.

Dr. Camel's Conclusion

The desert of RA treatment can be a desolate place for patients who don't respond to traditional therapies. This review suggests that rituximab might be a hidden oasis, offering hope for patients who have not found relief from conventional treatments. The findings provide valuable insights into the potential of this medication, urging us to explore its use further and personalize treatment approaches for RA patients.

Date :
  1. Date Completed 2016-06-16
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

25054600

DOI: Digital Object Identifier

S2255-5021(14)00068-6

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.